MRC (Medical Research Council) Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
JAMA Psychiatry. 2019 Aug 1;76(8):834-842. doi: 10.1001/jamapsychiatry.2019.0774.
Early-life exposures, such as prenatal maternal lifestyle, illnesses, nutritional deficiencies, toxin levels, and adverse birth events, have long been considered potential risk factors for neurodevelopmental disorders in offspring. However, maternal genetic factors could be confounding the association between early-life exposures and neurodevelopmental outcomes in offspring, which makes inferring a causal relationship problematic.
To test whether maternal polygenic risk scores (PRSs) for neurodevelopmental disorders were associated with early-life exposures previously linked to the disorders.
DESIGN, SETTING, AND PARTICIPANTS: In this UK population-based cohort study, 7921 mothers with genotype data from the Avon Longitudinal Study of Parents and Children (ALSPAC) underwent testing for association of maternal PRS for attention-deficit/hyperactivity disorder (ADHD PRS), autism spectrum disorder (ASD PRS), and schizophrenia (SCZ PRS) with 32 early-life exposures. ALSPAC data collection began September 6, 1990, and is ongoing. Data were analyzed for the current study from April 1 to September 1, 2018.
Maternal ADHD PRS, ASD PRS, and SCZ PRS were calculated using discovery effect size estimates from the largest available genome-wide association study and a significance threshold of P < .05.
Outcomes measured included questionnaire data on maternal lifestyle and behavior (eg, smoking, alcohol consumption, body mass index, and maternal age), maternal use of nutritional supplements and medications in pregnancy (eg, acetaminophen, iron, zinc, folic acid, and vitamins), maternal illnesses (eg, diabetes, hypertension, rheumatism, psoriasis, and depression), and perinatal factors (eg, birth weight, preterm birth, and cesarean delivery).
Maternal PRSs were available from 7921 mothers (mean [SD] age, 28.5 [4.8] years). The ADHD PRS was associated with multiple prenatal factors, including infections (odds ratio [OR], 1.11; 95% CI, 1.04-1.18), use of acetaminophen during late pregnancy (OR, 1.11; 95% CI, 1.04-1.18), lower blood levels of mercury (β coefficient, -0.06; 95% CI, -0.11 to -0.02), and higher blood levels of cadmium (β coefficient, 0.07; 95% CI, 0.05-0.09). Little evidence of associations between ASD PRS or SCZ PRS and prenatal factors or of association between any of the PRSs and adverse birth events was found. Sensitivity analyses revealed consistent results.
These findings suggest that maternal risk alleles for neurodevelopmental disorders, primarily ADHD, are associated with some pregnancy-related exposures. These findings highlight the need to carefully account for potential genetic confounding and triangulate evidence from different approaches when assessing the effects of prenatal exposures on neurodevelopmental disorders in offspring.
早期生活暴露,如产前母亲的生活方式、疾病、营养缺乏、毒素水平和不良出生事件,长期以来一直被认为是后代神经发育障碍的潜在危险因素。然而,母亲的遗传因素可能会混淆早期生活暴露与后代神经发育结果之间的关联,这使得推断因果关系成为一个问题。
测试母亲的神经发育障碍多基因风险评分(PRS)是否与先前与该疾病相关的早期生活暴露有关。
设计、地点和参与者: 在这项基于英国人群的队列研究中,7921 名来自阿冯纵向研究父母和儿童(ALSPAC)的母亲有基因型数据,她们接受了注意力缺陷/多动障碍(ADHD PRS)、自闭症谱系障碍(ASD PRS)和精神分裂症(SCZ PRS)的母亲 PRS 与 32 种早期生活暴露的关联测试。ALSPAC 的数据收集始于 1990 年 9 月 6 日,目前仍在进行中。本研究的数据于 2018 年 4 月 1 日至 9 月 1 日进行分析。
使用来自最大的全基因组关联研究的发现效应大小估计值和 P<0.05 的显著性阈值计算母亲的 ADHD PRS、ASD PRS 和 SCZ PRS。
测量的结果包括母亲生活方式和行为(例如,吸烟、饮酒、体重指数和母亲年龄)的问卷调查数据、母亲在怀孕期间使用的营养补充剂和药物(例如,对乙酰氨基酚、铁、锌、叶酸和维生素)、母亲的疾病(例如,糖尿病、高血压、风湿病、银屑病和抑郁症)以及围产期因素(例如,出生体重、早产和剖宫产)。
7921 名母亲(平均[标准差]年龄,28.5[4.8]岁)有母亲 PRS。ADHD PRS 与多种产前因素有关,包括感染(比值比[OR],1.11;95%置信区间[CI],1.04-1.18)、妊娠晚期使用对乙酰氨基酚(OR,1.11;95%CI,1.04-1.18)、汞血水平降低(β系数,-0.06;95%CI,-0.11 至-0.02)和镉血水平升高(β系数,0.07;95%CI,0.05-0.09)。发现 ASD PRS 或 SCZ PRS 与产前因素之间几乎没有关联,也没有任何 PRS 与不良出生事件之间的关联。敏感性分析显示出一致的结果。
这些发现表明,神经发育障碍(主要是 ADHD)的母亲风险等位基因与一些与妊娠相关的暴露有关。这些发现强调了在评估产前暴露对后代神经发育障碍的影响时,需要仔细考虑潜在的遗传混杂,并从不同方法中综合证据。